When tested in vivo, T-cells expressing FGFR4.28HTM.28z-CD276.8HTM.BBz BiCisCAR exhibited faster tumor eradication, increased persistence, and reduced expression of exhaustion markers such as CD39, PD-1, and LAG-3 (Fig. 3G–L). Here, CD276 is linked to neoplasm.